We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Vegums develop multivitamin gummies for a vegan and plant-based lifestyle. The company argues that some vitamins are difficult to get from a plant-only diet, such as vitamin D, B12, and iodine. Vegums has researched and incorporated non-animal vitamin ingredients into its products to address that issue. The company asserts that its products are 100% plastic-free and biodegradable. It claims that the number of vegans in the UK grew by 40% in 2020, and shows no sign of slowing down in 2021. It aims to become a contender in this segment. Vegums won the World Plant Award 2020 for the 'Best Plant-Based Start-Up', has a social media following of over 15,700 on Instagram, achieved 4.8/5 on TrustPilot, and scaled from selling 1 pack of Vegums to over 9,000 a month to its customers. It will use the investment for New Product Development (NPD), team expansion, and launching into new markets and countries.
days to go: Expired investment: £312,463
Medics2You's is a hybrid telehealth platform that connects patients with healthcare experts around the globe with focus on Africa through a smart device from anywhere, six days a week. The company has a pilot project underway in Nigeria, a nation which spends $500m-1bn annually on outbound healthcare tourism. Medics2You aims to reach out to over 100m people unable to access quality healthcare. Medics2You's partnership with Lantum has given the company access to 18000+ doctors and 3000 clinicians. The funds will be used to create the web portal, expand the team, set up local centres, and enhance marketing activities.

Pitch Rated

76%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £156,370
Ingle & Rhode has come up with ethical and traceable wedding bands and rings. The company has sold more than 6,000 rings directly to the customers. It has achieved a rating of 5-star on Trustpilot and became a finalist of 2015, 2016 and 2017 UK Jewellery Awards. They aim to offer an exceptional combination of premium quality and ethical credentials. With the proceeds, the company will boost its digital marketing campaign.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £118,080
Centaur Robotics is redefining mobility for the 10% of the global population who require assistance to walk 400 meters. Representing a £7 billion global opportunity, the company offers a blend of convenient service and innovative two-wheeled vehicle design, catering to individuals and collaborating with international brands in sectors such as airlines, shopping centers, retirement living, hotels, and restaurants. After a successful 2020 investment round, Centaur Robotics is currently seeking the final £65,000 of its seed equity round. This funding will facilitate pre-production market trials, design refinements, large-scale testing, and production expansion. With established commercial traction, the company aims for a full commercial launch by June 2024.
days to go: Expired investment: £795,101
JOHNNY'S is an ethical, vegan, and sex-positive subscription condom brand. The company aims to deliver its products on a subscription basis, following in the footsteps of Direct-To-Consumer (DTC) health disruptors like Harry's and Dollar Shave Club. It aims to become a contender in the global condom market that is set to be worth $15 Billion by 2026 and enter the lubricant and sex toy market later in 2021. The company has also pledged to give a condom to HIV/STI/NHS clinics for each condom sold. It will use the investment for a PR launch, social media advertising, stock purchase, and attract talent to help the business hit its growth targets.
days to go: Expired investment: £182,281
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph